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Abstract
Background: Clinical trials are increasingly being conducted internationally. In order to ensure enrollment of healthy
participants and proper safety evaluation of vaccine candidates, established reference intervals for clinical tests are required
in the target population.
Methodology/Principal Findings: We report a reference range study conducted in Ugandan adult blood bank donors
establishing reference intervals for hematology and clinical chemistry parameters. Several differences were observed when
compared to previously established values from the United States, most notably in neutrophils and eosinophils.
Conclusions/Significance: In a recently conducted vaccine trial in Uganda, 31 percent (n=69) of volunteers screened
(n=223) were excluded due to hematologic abnormalities. If local reference ranges had been employed, 83% of those
screened out due to these abnormalities could have been included in the study, drastically reducing workload and cost
associated with the screening process. In addition, toxicity tables used in vaccine and drug trial safety evaluations may need
adjustment as some clinical reference ranges determined in this study overlap with grade 1 and grade 2 adverse events.
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Introduction
Substantial efforts are underway to develop and test HIV
vaccines internationally. The first priority in vaccine development
is the evaluation of safety and tolerability in the clinically
‘‘normal’’ adult population. In order to accurately assess what is
healthy, reference intervals for standard laboratory tests in the
target population are necessary. Use of improper clinical reference
ranges may falsely exclude otherwise eligible volunteers from
participating in vaccine trials, making the process of trial
enrollment and execution more challenging. In addition, clinical
reference intervals in a population are necessary in order to
accurately assess potential adverse vaccine reactions observed
during the course of a clinical trial.
Common practice in Uganda, both in hospitals and research
laboratories, is to use the manufacturer’s ranges for a given clinical
laboratory assay system. Many of these assay systems are procured
from Europe or the United States and use reference values based
on their populations, which may not be representative of the
Ugandan population. Numerous publications describe differences
between clinical reference ranges in African populations compared
to industrialized countries [1,2,3,4,5]. A small number of
publications address reference values in Uganda [4,6], but these
are limited in scope to hematologic and selected lymphocyte
parameters or restricted geographically to rural areas of Uganda.
In November 2004, screening for enrollment in a Phase I HIV
vaccine trial to assess the safety and immunogenicity of a multiclade
HIV-1 DNA plasmid vaccine (VRC-HIVDNA009-00-VP, Vaccine
Research Center, National Institute of Health, Bethesda, Maryland)
began at the Makerere University Walter Reed Project (MUWRP)
in Kampala, Uganda. [7] The trial enrolled 31 healthy Ugandan
volunteers, with inclusion criteria based on clinical reference ranges
obtained from US sources. Due to numerous exclusions based on
laboratory abnormalities, the screening to enrollment ratio was
extremely high (7 volunteers screened for every 1 trial participant).
These numbers present enormous logistical, personnel and financial
issues for movement of vaccine candidates into phase II and phase
III trials, thus more appropriate reference ranges are needed. In
addition, population relevant clinical reference ranges would aid
clinicians in patient management in Uganda.
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3919This study establishes the reference ranges for hematology and
chemistry values in anonymous, healthy, adult Ugandan blood
bank donors in the Kampala region and evaluates their potential
implications in vaccine trials.
Materials and Methods
Blood Bank
The Nakasero Blood Bank, in Kampala, is the central
laboratory for the Uganda Blood Transfusion Service (UBTS).
The UBTS supplies over 140,000 units of blood per year to
Ugandan hospitals. Blood donations are derived from the
donation center in Kampala and at multiple donation centers
throughout the country. In accordance with Ugandan National
blood donation policy and practices, a confidential pre-donation
evaluation is conducted by a trained health counselor to determine
eligibility to donate blood. Questions include information about
blood transfusion history’ number of sexual partners’ use of non-
sterilized needles’ prolonged fever or frequent infections’ history of
liver disease or hepatitis’ and medication history. In addition’ a
general physical examination including general appearance’
lymphadenopathy’ weight, height’ blood pressure’ and tempera-
ture is performed by a health specialist trained by the UBTS. A
copper sulfate test is used to ensure adequate hemoglobin levels in
blood donors. As a result of the screening process’ the HIV
prevalence in the blood donor population has been reduced from
approximately 14 percent in 1987 to 2 percent in 2003. (personal
communication, Dr. Peter Kataaha, Director UBTS) These
procedures ensured that blood collection occurred in those donors
that were generally healthy.
Participation in this study was anonymous as no linkage was
present between the blood donor and samples. The only
demographic information collected was gender, age and regional
collection site. All donors found eligible as a result of the blood
bank screening process were asked to participate in this study.
Donors willing to participate were required to complete a written
donor affidavit form, consenting to donate residual blood for
research purposes. The study received ethical approval from the
Makerere University Faculty of Medicine Research and Ethics
Committee and the Uganda National Council of Science and
Technology in Uganda and from the Walter Reed Army Institute
of Research Institutional Review Board in the United States.
Sample collection
After standard blood collection in a polyethylene donation bag,
residual blood remaining in the tubing was collected into 3ml
EDTA and serum collection vacutainers. The tubing was
manually clamped at the bag to prevent backflow of blood and/
or anticoagulant from the bag into the tubing. Samples were
transported at room temperature in sealed boxes to the College of
American Pathologists (CAP) accredited MUWRP laboratory,
located in Kampala, Uganda. Only those samples received in the
laboratory within 8 hours of phlebotomy were included in the
study. All samples were collected between July and September
2005.
Hematology and Chemistry Testing
Hematology analysis, including a complete blood count and five
part differential, was performed on EDTA anticoagulated blood
using the Coulter AcT5 diff (Beckman Coulter, Fullerton,
California). Serum vacutainers were centrifuged at 8006g and
serum was aliquoted for use on Roche Cobas Integra 400 plus
analyzer (Roche, Indianapolis, Indiana). Tests were performed on
both platforms in strict adherence to manufacturer’s instructions.
Exclusion from reference range data set
All samples were tested for HIV antibody, Hepatitis B surface
Antigen, Hepatitis C Antibody, and pregnancy. All test kits were
approved by the US Food and Drug Administration (FDA).
Samples found to be positive in any of these tests were excluded
from the data set.
Initial screening for anti-HIV-1 antibody was conducted using
Genetic Systems rLAV ELISA (BioRad Laboratories, Redmond,
WA). Reactive samples were repeated in duplicate using the
Vironostika HIV-1 Microelisa Systems (Organon Teknika,
Durham, North Carolina). Samples repeatedly reactive by both
ELISAs were tested using the Genetic Systems HIV-1 Western
Blot (BioRad Laboratories, Redmond, WA). Screening for
Hepatitis B surface antigen (HBsAg) was performed using the
Genetic Systems HBsAg EIA 3.0 (BioRad Laboratories, Red-
mond, WA). Repeatedly reactive samples were confirmed using
the Genetic Systems Confirmatory Assay 3.0 (BioRad Laborato-
ries, Redmond, WA). Screening for anti-Hepatitis C antibody was
performed using the Ortho HCV Version 3.0 ELISA Tests
System. Repeatedly reactive samples were tested in the Chiron
RIBA HCV 3.0 SIA (Chiron Corporation, Emeryville, CA).
Serum pregnancy testing was performed on all females using
Wampole PreVue hCG cassettes. (Wampole Laboratories, Inc
Dist., Princeton, NJ)
Statistical methods
Ranges were calculated using JMP 5.1 (SAS Institute, Cary,
NC, USA). The reference range intervals were calculated as the
range between those values at the 2.5% and 97.5% limits for the
population after exclusions listed above, stratified by gender, thus
providing the reference range encompassing 95% of the
population. The non-parametric Wilcoxon test was used to
determine any statistically significant differences between labora-
tory values for men and women.
Results
Sample collection results
Of 960 samples collected and received in the laboratory, 8%
(78/960) were excluded due to laboratory abnormalities (1%
positive for HIV Antibody; 4% positive for Hepatitis B Surface
Antigen; 3% positive or indeterminate for Hepatitis C Antibody;
3% of females were pregnant). Another 2% (20/960) were
excluded from the analysis due to missing data. Following these
exclusions, 862 samples were included for clinical reference range
determination. Most analytes had far fewer samples included due
to issues with sample volume or test availability (Tables 1 and 2),
but the number of subjects tested for each analyte was within the
sample size (N=120) suggested by CLSI.[8] The gender
distribution was 20% female and 80% male and the median age
was 23 years (male:24, female:20), with a range of 18 to 56. Most
volunteers (73%) were below the age of 30.
Hematology and Chemistry Reference Ranges
Hematologic reference ranges, mean and median values are
presented in Table 1. Statistically significant (p,0.05) gender
differences were seen in most parameters, with the exception of the
red blood cell indices (MCV, MCH, MCHC), absolute monocyte
count and absolute basophil count, but these differences were not
clinically relevant. In comparing these values with those obtained
from the Massachusetts General Hospital (MGH) in the United
States [9], there were several noticeable differences. The lower
limit of the neutrophil percentage range was considerably
decreased in the Ugandan population (22%) compared with the
Ugandan Reference Intervals
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percentages was drastically increased (25% in Uganda vs. 8% at
MGH). The lower range of the red blood cell parameters (RBC,
Hemoglobin, Hematocrit) was also decreased in the Ugandan
population.
Chemistry reference intervals were established for 24 analytes
including electrolytes, liver function tests, renal function tests, lipid
profile, cardiac enzymes and others. Mean and median values
along with the 2.5–97.5% ranges are presented in Table 2. There
were statistically significant (p , 0.05) differences between men
and women for fifteen laboratory parameters. Most tests were in
agreement with reference intervals published in the US.[9]
Differences in cholesterol and triglyceride values are likely due
to the fact that samples in our study were not collected from fasting
individuals. Two enzymes, Creatine Kinase (CK) and Lactose
Dehydrogenase (LDH) had upper ranges that were substantially
higher than the published MGH ranges(See Table 2)[9]. In
contrast, the upper limit of the Lipase range was much lower in the
Ugandan population (68 U/L) compared to the MGH upper
range (160 U/L) although it was within the range given by the
instrument manufacturer. (13–60 U/L).[10]
Discussion
Reference ranges were established for hematology and chem-
istry parameters using samples derived from anonymous blood
bank donors. Although the number of females was disproportion-
ate to males (20% vs. 80%) in this study, the number of females
included in reference range determination for each analyte was
well within the guidelines of CLSI of 120 subjects[8]. The lower
proportion of females is likely due to less frequent participation in
blood drives and other medical research due to cultural issues. The
low prevalence of Hepatitis B surface antigen, Hepatitis C
Antibody and HIV antibody in this group demonstrates the
success of the blood bank’s screening questionnaire as a method
for eliminating donors with pathological conditions or acute
illnesses that may have an impact on blood safety. Although a
detailed medical history outlined by the CLSI guideline[8],
including history of tobacco use, diet, alcohol consumption,
fasting status, exercise history, genetic or environmental factors,
occupation and socio-economic status could not be obtained and
utilized in this study, the rigorous screening process employed by
the blood bank presumably resulted in collection from overall
healthy adults. Furthermore, the blood bank population is likely to
be similar to one that would participate in vaccine trials, making
these reference ranges directly applicable to that population.
Hematology ranges derived in this study were comparable to
published values in Uganda using identical methodology[4],
despite the fact that the previous study focused on rural areas
and the health status of the volunteers was largely unknown. Red
blood cell parameter and platelet findings were consistent with
other published African values[2,4,5], with Ugandans having
lower levels than subjects from industrialized nations. As has been
previously shown in other African countries[11,12,13], our
analysis revealed drastically higher eosinophil counts than
published values derived from the United Sates[9] and is likely a
result of the high prevalence of parasitic infestations in Africa[4].
The observed neutropenia in this study has also been previously
documented[1,11,12,14,15], although the cause is still unknown.
In contrast with other African studies[2,4,16], our data showed
significant gender differences between white blood cells and most
differential parameters.
Clinical chemistry reference values have not been previously
published in Uganda. In contrast with hematologic ranges,
chemistry ranges were similar to those published in the United
States with a few exceptions. CK and LDH values were
substantially higher than those published for the US. Exercise is
known to elevate levels of these enzymes[17] and perhaps the
topography of Kampala combined with the socio-economic status
of the donors compared to the US and Europe may lead to more
daily physical exercise in the Ugandan group. Additionally, racial
differences in creatine kinase levels have been documented and
may be contributing to this disparity.[18]
Calculation of region specific reference ranges is not only
important for improving quality of health care, but also for
implementation of vaccine trials. The impact of utilization of local
reference ranges may be significant in reducing screening to
enrollment ratios in clinical trials. Our program recently screened
223 volunteers for a phase I vaccine trial in Kampala, Uganda in
2004–2005. As local reference ranges had not been established,
US based reference ranges were used for inclusion/exclusion
criteria. These inclusion/exclusion criteria included: 1) White
blood cell count: 3,300–12,000 cells/ml; 2) Hemoglobin: .11g/L
(females) and .12.5 g/L (males); 3) Neutrophils: 32–66% or
.1,500 cells/ml 4)Lymphocytes: 28–61% or .800 cells/ml; 5)
Eosinophils: 0–8% or #400 cells/ml; 6)Platelet count: 125,000–
550,000 cells/ml. A total of 69 volunteers were excluded due to
apparent hematology abnormalities. However if locally derived
reference intervals had been utilized, 57 of these volunteers (83%)
could have been included (Table 3). Additionally, the time period
for trial enrollment could have theoretically been reduced from 4
months to approximately 3 months. A reduction in the number of
volunteers screened would impact dramatically both daily
workload and cost. For example, the personnel cost (clinic and
laboratory) for conducting screening visits for the additional 57
volunteers in this vaccine study was approximately $17,000 (US).
The extra clinical supplies and lab tests associated with the
additional screening cost approximately $10,300 (US). In
personnel and lab supply costs alone these additional volunteers
increased the cost of the study by $27,000 (US).
Equally important, the toxicity tables used for grading adverse
events may need re-evaluation based on clinical reference ranges
from the developing world (Table 4). In particular, the NIH
Division of AIDS (DAIDS) table for grading the severity of adult
and pediatric adverse events (http://www3.niaid.nih.gov/
research/resources/DMIDClinRsrch/toxtables.htm) used in
many clinical trials may not reflect locally established country
specific reference ranges. For example, the range for absolute
neutrophils established in this study has a lower limit of 0.9610ˆ3
cells/ul, although this value would qualify as a grade 2 adverse
Table 3. Vaccine Trial Exclusions
# excluded
# excluded if
updated ranges used
Neutropenia 24 3
Eosinophilia 27 4
Neutropenia+Eosinophilia 92
Low Hemoglobin 40
Thrombocytopenia 21
Leucopenia 32
Totals 69 12
doi:10.1371/journal.pone.0003919.t003
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coincide with a grade 1 adverse event.
Ideally, a reference range study should be conducted as an
independent investigation, with carefully designed questionnaires,
exclusion/inclusion criteria and a comprehensive sampling plan,
according to CLSI guidelines[8]. These studies are time
consuming, logistically difficult and quite expensive. Most
published reference range studies in Africa [2,3,4,5,6] have used
existing studies/protocols (cohort development, HIV studies, etc)
in order to gather data. Some studies have had strict criteria for
sample inclusion [2] while the two studies in Uganda required only
a negative HIV test [4,6]. Our study used a similar approach as
the previous African studies, although a brief physical exam as
described earlier went one step further towards ensuring
participation of generally healthy donors. Several limitations are
apparent in the design of our study, mostly importantly the lack of
detailed information to rule out subclinical conditions. We
conducted this study within the framework of the bloodbank’s
existing procedures, without additional staff or infrastructure and
without resources spent on volunteer recruitment. In order to
minimize interference in daily activities, very limited extraneous
information was collected. A second limitation of this study is the
calculation of ranges based on a very specific population. Although
the blood bank population can be described as a self-selected
population, this is in fact, similar to a population that might
participate in clinical trials. In a developing country, where
resources are limited, we believe that our study methods were
adequate to determine reference ranges in a setting where this type
of information is limited.
Despite the stated limitations of the study, we assert that the
ranges generated in this study would be suitable for use in a more
generalized setting, especially in the absence of other relevant
data. It is possible that these ranges could be extrapolated to other
regions in East Africa or other regions of Africa, of similar altitudes
and environments, however small bridging studies according to
CLSI guidelines[8] should be performed in order to validate these
ranges in a new population. Our study confirms previous findings
that regional differences exist for clinical reference intervals. These
intervals are critical for successful evaluation of vaccines and drugs
internationally and also for advancing basic health care services in
the developing world.
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